יתרות מזומנים למניה Cryo-Cell International, Inc. (CCEL)

Cryo-Cell International (CCEL) maintains a flawless express delivery network for biomaterials that guarantees sample integrity, as evidenced by the quarterly cash per share. The value of 0.52 reflects this liquidity status. Leadership in stem cell storage relies on long-standing authority and the scale of its capacities. The development strategy is based on expanding the cryobank and implementing regenerative treatment methods for severe pathologies.
פילוחים אנליטיים של חברת Cryo-Cell International

For Cryo-Cell International (CCEL), which develops cell therapy methods, this indicator determines the liquid safety cushion per common share. The metric is calculated by dividing total cash holdings by the number of issued shares, measuring the intrinsic value of the assets. By analyzing the cash per share, an investor assesses the business's resilience to interest rate fluctuations. These resources are critical for the long-term funding of R&D in regenerative medicine. A stable capital balance ensures the uninterrupted release of new products without the risk of default.